EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY 4.0

Loss of p16 expression is a sensitive marker of CDKN2A homozygous deletion in malignant meningiomas

Vivian Tang, Rufei Lu, Kanish Mirchia, Jessica Van Ziffle, Patrick Devine, Julieann Lee, Joanna J Phillips, Arie Perry, David R Raleigh, Calixto-Hope G Lucas, David A Solomon iD

Acta Neuropathologica · 2023

DOI: 10.1007/s00401-023-02544-6 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Acta Neuropathologica, 2023. Verfasst von Vivian Tang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of California San Francisco, 513 Parnassus Ave, Health Sciences West 451, San Francisco, CA, 94143, USA. Hauptthemen laut MEDLINE: Meningioma, Meningeal Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NCI NIH HHS, ODCDC CDC HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeningiomaMeningeal NeoplasmsHumansHomozygoteSequence DeletionGenes, p16Cyclin-Dependent Kinase Inhibitor p16

Substanzen

Cyclin-Dependent Kinase Inhibitor p16CDKN2A protein, human

Autor:innen und Institutionen

  • Department of Pathology, University of California San Francisco, 513 Parnassus Ave, Health Sciences West 451, San Francisco, CA, 94143, USA.
  • Clinical Cancer Genomics Laboratory, University of California San Francisco, San Francisco, CA, USA.
  • Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
  • Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
  • Department of Pathology, University of California San Francisco, 513 Parnassus Ave, Health Sciences West 451, San Francisco, CA, 94143, USA. clucas7@jhmi.edu.
  • Department of Pathology, Johns Hopkins University School of Medicine, 1800 Orleans St, Sheikh Zayed Tower Room 2101, Baltimore, MD, 21287, USA. clucas7@jhmi.edu.

ORCID-Profile: David A Solomon

Förderung

  • NIH HHS
  • NCI NIH HHS
  • ODCDC CDC HHS
  • NIH Office of the Director
  • National Cancer Institute, NIH

Zitieren

APA

Tang, V., Lu, R., Mirchia, K., Van Ziffle, J., Devine, P., Lee, J., Phillips, J. J., Perry, A., Raleigh, D. R., Lucas, C. G., & Solomon, D. A. (2023). Loss of p16 expression is a sensitive marker of CDKN2A homozygous deletion in malignant meningiomas. Acta Neuropathologica. https://doi.org/10.1007/s00401-023-02544-6

Vancouver

Tang V, Lu R, Mirchia K, Van Ziffle J, Devine P, Lee J, et al. Loss of p16 expression is a sensitive marker of CDKN2A homozygous deletion in malignant meningiomas. Acta Neuropathologica. 2023. doi:10.1007/s00401-023-02544-6

BibTeX
@article{Tang2023,
  author = {Tang, Vivian and Lu, Rufei and Mirchia, Kanish and Van Ziffle, Jessica and Devine, Patrick and Lee, Julieann and Phillips, Joanna J and Perry, Arie and Raleigh, David R and Lucas, Calixto-Hope G and Solomon, David A},
  title = {Loss of p16 expression is a sensitive marker of CDKN2A homozygous deletion in malignant meningiomas},
  journal = {Acta Neuropathologica},
  year = {2023},
  doi = {10.1007/s00401-023-02544-6}
}
Kostenlos starten →